Abstract：Objective To explore the research progress on pathogenesis and clinical characteristics of leukoaraiosis (LA).Methods Literatures from January 1987 to January 2016 in PubMed database, CNKI database and Wanfang database with the key words “leukoaraiosis, white matter hyperintensities, white matter lesions.” Literatures about the pathogenesis and clinical characteristics of LA were selected and reviewed.Results LA is frequently seen on MRI scans of the brain in older people and is characterised as bilateral, mostly symmetrical hyperintensities on T2WI and FLAIR sequences. Age and hypertension are the most recognized risk factors for LA. Chronic hypoperfusion and blood-brain barrier damage are deemed to be conceivable pathogenesis for LA. LA also seems to be a major contributor of cognitive decline and has presentation of functional loss, like emotional disorder, gait problems or uracratia dysfunction.Conclusions LA is common in aged population and has multiple clinical manifestations. It may be caused by cerebral small vessel disease, while the mechanism and therapeutic strategy of LA still need to be studied.
钟婷婷, 周华东. 脑白质疏松症发病机制及临床特点的研究进展[J]. 中华解剖与临床杂志, 2017, 22(2): 171-174.
Zhong Tingting, Zhou Huadong.. Research progress on pathogenesis and clinical characteristics of leukoaraiosis. Chinese Journal of Anatomy and Clinics, 2017, 22(2): 171-174.
Hachinski VC, Potter P, Merskey H. Leuko-araiosis[J]. Arch Neurol, 1987, 44(1): 21-23. DOI:10.1001/archneur.1987.00520130013009
[2]
Chen A, Akinyemi RO, Hase Y, et al. Frontal white matter hyperintensities, clasmatodendrosis and gliovascular abnormalities in ageing and post-stroke dementia[J]. Brain, 2016, 139(Pt 1): 242-258. DOI:10.1093/brain/awv328
[3]
Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update[J]. Nat Rev Neurol, 2015, 11(3): 157-165. DOI:10.1038/nrneurol.2015.10
[4]
Schmidt R, Ropele S, Enzinger C, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study[J]. Ann Neurol, 2005, 58(4): 610-616. DOI: 10.1002/ana.20630
[5]
van Dijk EJ, Prins ND, Vrooman HA, et al. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study[J]. Stroke, 2008, 39(10): 2712-2719. DOI:10.1161/STROKEAHA.107.513176
[6]
Simoni M, Li L, Paul NL, et al. Age- and sex-specific rates of leukoaraiosis in TIA and stroke patients: population-based study[J]. Neurology, 2012, 79(12): 1215-1222. DOI:10.1212/WNL.0b013e31826b951e
[7]
Barber R, Scheltens P, Gholkar A, et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging[J]. J Neurol Neurosurg Psychiatr, 1999, 67(1): 66-72. DOI:10.1136/jnnp.67.1.66
[8]
Lee SJ, Kim JS, Lee KS, et al. The leukoaraiosis is more prevalent in the large artery atherosclerosis stroke subtype among Korean patients with ischemic stroke[J]. BMC Neurol, 2008, 8: 31. DOI:10.1186/1471-2377-8-31
[9]
Pantoni L, Basile AM, Pracucci G, et al. Impact of age-related cerebral white matter changes on the transition to disability—the LADIS study: rationale, design and methodology[J]. Neuroepidemiology, 2005, 24(1-2): 51-62. DOI:10.1159/000081050
[10]
Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration[J]. Lancet Neurol, 2013, 12(8): 822-838. DOI:10.1016/S1474-4422(13)70124-8
[11]
Maniega SM, Valdés Hernández MC, Clayden JD, et al. White matter hyperintensities and normal-appearing white matter integrity in the aging brain[J]. Neurobiol Aging, 2015, 36(2): 909-918. DOI:10.1016/j.neurobiolaging.2014.07.048
[12]
Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging[J]. Lancet Neurol, 2013, 12(5): 483-497. DOI:10.1016/S1474-4422(13)70060-7
[13]
van der Veen PH, Muller M, Vincken KL, et al. Longitudinal relationship between cerebral small-vessel disease and cerebral blood flow: the second manifestations of arterial disease-magnetic resonance study[J]. Stroke, 2015, 46(5): 1233-1238. DOI:10.1161/STROKEAHA.114.008030
[14]
Simpson JE, Wharton SB, Cooper J, et al. Alterations of the blood-brain barrier in cerebral white matter lesions in the ageing brain[J]. Neuroscience Letters, 2010, 486(3): 246-251. DOI:10.1016/j.neulet.2010.09.063
[15]
Chung CP, Wang PN, Wu YH, et al. More severe white matter changes in the elderly with jugular venous reflux[J]. Ann Neurol, 2011, 69(3): 553-559. DOI:10.1002/ana.22276
[16]
Verhaaren BF, Vernooij MW, de Boer R, et al. High blood pressure and cerebral white matter lesion progression in the general population[J]. Hypertension, 2013, 61(6): 1354-1359. DOI:10.1161/HYPERTENSIONAHA.111.00430
[17]
Wardlaw JM, Allerhand M, Doubal FN, et al. Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities[J]. Neurology, 2014, 82(15): 1331-1338. DOI:10.1212/WNL.0000000000000312
[18]
Fornage M, Debette S, Bis JC, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium[J]. Ann Neurol, 2011, 69(6): 928-939. DOI:10.1002/ana.22403
[19]
Hofer E, Cavalieri M, Bis JC, et al. White matter lesion progression: genome-wide search for genetic influences[J]. Stroke, 2015, 46(11):3048-3057. DOI:10.1161/STROKEAHA.115.009252
[20]
Kloppenborg RP, Nederkoorn PJ, Geerlings MI, et al. Presence and progression of white matter hyperintensities and cognition: a meta-analysis[J]. Neurology, 2014, 82(23): 2127-2138. DOI:10.1212/WNL.0000000000000505
[21]
Mortamais M, Artero S, Ritchie K. White matter hyperintensities as early and independent predictors of Alzheimer's disease risk[J]. J Alzheimers Dis, 2014, 42(Suppl 4): S393-S400. DOI:10.3233/JAD-141473
[22]
Alexopoulos GS. Depression in the elderly[J]. Lancet, 2005, 365(9475): 1961-1970. DOI:10.1016/S0140-6736(05)66665-2
[23]
Fujishima M, Maikusa N, Nakamura K, et al. Mild cognitive impairment, poor episodic memory, and late-life depression are associated with cerebral cortical thinning and increased white matter hyperintensities[J]. Front Aging Neurosci, 2014, 6: 306. DOI:10.3389/fnagi.2014.00306
[24]
Tighe SK, Reading SA, Rivkin P, et al. Total white matter hyperintensity volume in bipolar disorder patients and their healthy relatives[J]. Bipolar Disord, 2012, 14(8): 888-893. DOI:10.1111/bdi.12019
[25]
Smith EE, O'Donnell M, Dagenais G, et al. Early cerebral small vessel disease and brain volume, cognition, and gait[J]. Ann Neurol, 2015, 77(2): 251-261. DOI:10.1002/ana.24320
[26]
Soumaré A, Elbaz A, Zhu Y, et al. White matter lesions volume and motor performances in the elderly[J]. Ann Neurol, 2009, 65(6): 706-715. DOI:10.1002/ana.21674
[27]
Kuchel GA, Moscufo N, Guttmann CR, et al. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults[J]. J Gerontol A Biol Sci Med Sci, 2009, 64(8): 902-909. DOI:10.1093/gerona/glp037
[28]
Wehrberger C, Jungwirth S, Fischer P, et al. The relationship between cerebral white matter hyperintensities and lower urinary tract function in a population based, geriatric cohort[J]. Neurourol Urodyn, 2014, 33(4): 431-436. DOI:10.1002/nau.22419
[29]
Weber R, Weimar C, Blatchford J, et al. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy[J]. Stroke, 2012, 43(9): 2336-2342. DOI:10.1161/STROKEAHA.111.648576
[30]
Xiong Y, Wong A, Cavalieri M, et al. Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities[J]. Neurotherapeutics, 2014, 11(3): 606-611. DOI:10.1007/s13311-014-0270-5
2017, Vol. 22 
